An observational study in Migraine and Alexithymia, sponsored by Azienda Sanitaria Locale di Alessandria. Enrolling by invitation at 1 site in Italy. Open to female participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Azienda Sanitaria Locale di Alessandria · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Migraine Disorders with a site in Italy — 37 open to participants now, 47 under way, 13 of them phase 3. Migraine Disorders · Italy.
Among the 115 studies in Migraine Disorders with a site in Italy, this one is the 11th largest by planned enrollment of the 42 observational ones that give a count, is one of 12 that started in 2022, is one of 42 observational ones, reaches primary completion later than 35 of the 46 other live ones, and was the 102nd registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →37 of the 115 studies in Migraine Disorders with a site in Italy are open now. Recruiting first, the newest first:
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 18–75 · Healthy volunteers
University of Roma La Sapienza · Sites in Italy
Ages 18–65
Istituto Auxologico Italiano · Sites in Italy
Ages 18–70
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 18–65
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 12 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 315 across the 73 interventional studies, 108 across the 42 observational. Of the 58 that completed or were terminated, 26 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 115 have an industry lead sponsor. The 10 most frequent:
Azienda Sanitaria Locale di Alessandria is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Azienda Sanitaria Locale di Alessandria has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Migraine Disorders with a site in Italy that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 15 to your calendar (.ics) → With an account.
Among the 115 studies in Migraine Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this observational, cross-sectional study is to investigate the relationship between alexithymia and migraine frequency (considering alexithymia a condition that can influence the severity of the clinical phenotype of migraine, favoring its chronicization), in an analysis adjusted for psychiatric comorbidity (for anxiety and depression, potentially influencing migraine chronicization) and for personalogical factor represented by apathy.
Female patients, aged 12-65 years, diagnosed with episodic migraine with or without aura, chronic migraine and/or MOH according to ICHD-3 2018 criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Female patients, aged 12-65 years, diagnosed with episodic migraine without or with aura, chronic migraine, and/or MOH according to the criteria of ICHD-3 2018
Degree of alexithymia
Independent variable measured as a score on the TAS-20 scale
Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval
Migraine frequency
Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval
Number of "drug days" in patients diagnosed with MOH
Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval
Degree of alessithymia in patients diagnosed with MOH
Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Jun 2027, 61 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2025 → Jun 2027 and completion Dec 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Sanitaria Locale di Alessandria